200 related articles for article (PubMed ID: 1544592)
1. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients.
Fioretti P; Gadducci A; Ferdeghini M; Prontera C; Malagnino G; Facchini V; Mariani G; Bianchi R
Gynecol Oncol; 1992 Feb; 44(2):155-60. PubMed ID: 1544592
[TBL] [Abstract][Full Text] [Related]
2. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Rispoli G; Prontera C; Bianchi R; Fioretti P
Scand J Clin Lab Invest Suppl; 1991; 207():19-24. PubMed ID: 1780685
[TBL] [Abstract][Full Text] [Related]
3. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.
Gadducci A; Ferdeghini M; Prontera C; Moretti L; Mariani G; Bianchi R; Fioretti P
Gynecol Oncol; 1992 Feb; 44(2):147-54. PubMed ID: 1312052
[TBL] [Abstract][Full Text] [Related]
4. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
5. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of TATI and other markers in solid tumors.
Taccone W; Mazzon W; Belli M
Scand J Clin Lab Invest Suppl; 1991; 207():25-32. PubMed ID: 1780686
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer.
Bian J; Li B; Kou XJ; Liu TZ; Ming L
Asian Pac J Cancer Prev; 2013; 14(11):6241-3. PubMed ID: 24377511
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids.
de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG
Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219
[TBL] [Abstract][Full Text] [Related]
10. Correlation of CA125 and CA19-9 serum levels with clinical course and second-look findings in patients with ovarian carcinoma.
Fioretti P; Gadducci A; Ferdeghini M; Bartolini T; Bianchi R; Facchini V
Gynecol Oncol; 1987 Nov; 28(3):278-83. PubMed ID: 3479380
[TBL] [Abstract][Full Text] [Related]
11. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
Halila H; Lehtovirta P; Stenman UH
Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
13. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
Medl M; Ogris E; Peters-Engl C; Leodolter S
Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
[TBL] [Abstract][Full Text] [Related]
14. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
Abu Hassaan SO
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
[TBL] [Abstract][Full Text] [Related]
15. The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer.
Fayed ST; Ahmad SM; Kassim SK; Khalifa A
Dis Markers; 1998 Nov; 14(3):155-60. PubMed ID: 10427474
[TBL] [Abstract][Full Text] [Related]
16. Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4.
Nishida Y; Kohno K; Kawamata T; Morimitsu K; Kuwano M; Miyakawa I
Gynecol Oncol; 1995 Mar; 56(3):357-61. PubMed ID: 7705668
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination.
Emoto S; Ishigami H; Yamashita H; Yamaguchi H; Kaisaki S; Kitayama J
Gastric Cancer; 2012 Apr; 15(2):154-61. PubMed ID: 21892754
[TBL] [Abstract][Full Text] [Related]
18. CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma.
Vergote IB; Abeler VM; Børmer OP; Stigbrand T; Tropé C; Nustad K
Tumour Biol; 1992; 13(3):168-74. PubMed ID: 1626181
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of serological tumor marker tests in patients with ovarian cancer].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1501-6. PubMed ID: 2573640
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
Fan HY; Duan DM; Liu YF
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]